Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis

Company Overview

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling. In parallel, Telomir maintains a preclinical pipeline of compounds designed to act on distinct molecular targets with the goal of delivering differentiated safety and efficacy profiles. Collaborative partnerships with academic institutions and contract research organizations support translational research efforts and accelerate compound progression from discovery through early clinical evaluation.

Headquartered in the United States, Telomir Pharmaceuticals is guided by an executive team with extensive experience in biopharmaceutical research, clinical development and regulatory affairs. While the company’s initial focus is on advancing its lead programs through clinical milestones in North America, management has articulated plans to pursue strategic alliances that could enable broader international development and commercialization. As a Nasdaq-listed entity, Telomir continues to refine its pipeline and expand its scientific platform with the goal of delivering innovative therapies to patients around the world.

Key Stats

• Today's Range: $1.36 to $1.41
• 50-Day Range: $1.13 to $2.29
• 52-Week Range: $1.12 to $8.40
• Volume: 401,802 shs
• Average Volume: 4.65 million shs
• Market Capitalization: $43.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Strong Buy

Telomir Pharmaceuticals Stock Analysis - MarketRank™

Telomir Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 760th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Telomir Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Telomir Pharmaceuticals has a consensus price target of $15.00, representing about 1,002.9% upside from its current price of $1.36.

Amount of Analyst Coverage

Telomir Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Telomir Pharmaceuticals are expected to grow in the coming year, from ($0.40) to ($0.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Telomir Pharmaceuticals is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Telomir Pharmaceuticals is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Telomir Pharmaceuticals has a P/B Ratio of 68.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.37% of the float of Telomir Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Telomir Pharmaceuticals has recently increased by 206.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Telomir Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Telomir Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.37% of the float of Telomir Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Telomir Pharmaceuticals has recently increased by 206.60%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.9 / 5
• News Sentiment: -0.43

News Sentiment

Telomir Pharmaceuticals has a news sentiment score of -0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Telomir Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 11 people have searched for TELO on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Telomir Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Telomir Pharmaceuticals insiders have not sold or bought any company stock.

TELO Stock Analysis - Frequently Asked Questions

How have TELO shares performed this year?

Telomir Pharmaceuticals' stock was trading at $4.12 on January 1st, 2025. Since then, TELO stock has decreased by 67.0% and is now trading at $1.36.

How were Telomir Pharmaceuticals' earnings last quarter?

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) posted its quarterly earnings data on Thursday, August, 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.09.

When did Telomir Pharmaceuticals IPO?

Telomir Pharmaceuticals (TELO) raised $7 million in an initial public offering (IPO) on Friday, February 9th 2024. The company issued 1,000,000 shares at a price of $7.00 per share. Kingswood Investments acted as the underwriter for the IPO.

Who are Telomir Pharmaceuticals' major shareholders?

Telomir Pharmaceuticals' top institutional shareholders include Geode Capital Management LLC (0.66%), Marshall Wace LLP (0.25%), Y Intercept Hong Kong Ltd (0.22%) and Jane Street Group LLC (0.17%).

How do I buy shares of Telomir Pharmaceuticals?

Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/13/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TELO
• Previous Symbol: NASDAQ:TELO
• CIK: 1971532
• Web: telomirpharma.com
• Phone: (737)-289-0835
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Telomir Pharmaceuticals: $15.00
• High Price Target: $15.00
• Low Price Target: $15.00
• Potential Upside/Downside: +1,002.9%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.53 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -4,595.08%
• Return on Assets: -1,750.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.39
• Quick Ratio: 2.39

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: 68.00

Miscellaneous

• Outstanding Shares: 32,281,000
• Free Float: N/A
• Market Cap: $43.90 million
• Optionable: N/A
• Beta: -0.73